Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 88

1.

Into darkness.

Kirsten A.

Nature. 2019 Jun;570(7760):270. doi: 10.1038/d41586-019-01798-z. No abstract available.

PMID:
31190017
2.

Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.

Watz H, Nagelschmitz J, Kirsten A, Pedersen F, van der Mey D, Schwers S, Bandel TJ, Rabe KF.

Pulm Pharmacol Ther. 2019 Jun;56:86-93. doi: 10.1016/j.pupt.2019.03.009. Epub 2019 Mar 24.

PMID:
30917927
3.

Dual bronchodilation with tiotropium/olodaterol further reduces activity-related breathlessness versus tiotropium alone in COPD.

Maltais F, Aumann JL, Kirsten AM, Nadreau É, Macesic H, Jin X, Hamilton A, O'Donnell DE.

Eur Respir J. 2019 Mar 28;53(3). pii: 1802049. doi: 10.1183/13993003.02049-2018. Print 2019 Mar.

4.

[The stepwise approach of COPD therapy].

Watz H, Kirsten A, Greulich T.

Dtsch Med Wochenschr. 2019 Jan;144(1):15-20. doi: 10.1055/a-0570-3595. Epub 2019 Jan 2. German.

PMID:
30602182
5.

Indacaterol acetate/mometasone furoate provides sustained improvements in lung function compared with salmeterol xinafoate/fluticasone propionate in patients with moderate-to-very-severe COPD: results from a Phase II randomized, double-blind 12-week study.

Beeh KM, Kirsten AM, Tanase AM, Richard A, Cao W, Hederer B, Beier J, Kornmann O, van Zyl-Smit RN.

Int J Chron Obstruct Pulmon Dis. 2018 Dec 6;13:3923-3936. doi: 10.2147/COPD.S179293. eCollection 2018.

6.

Longitudinal stability of blood eosinophil count strata in the COPD COSYCONET cohort.

Greulich T, Mager S, Lucke T, Koczulla AR, Bals R, Fähndrich S, Jörres RA, Alter P, Kirsten A, Vogelmeier CF, Watz H.

Int J Chron Obstruct Pulmon Dis. 2018 Sep 28;13:2999-3002. doi: 10.2147/COPD.S165909. eCollection 2018. No abstract available.

7.

[Perspectives for the Electroencephalogram in Psychiatry].

Kirsten A, Linder S, Olbrich S.

Praxis (Bern 1994). 2018 Jul;107(15):837-843. doi: 10.1024/1661-8157/a003028. Review. German.

PMID:
30043707
8.

A GATA3-specific DNAzyme attenuates sputum eosinophilia in eosinophilic COPD patients: a feasibility randomized clinical trial.

Greulich T, Hohlfeld JM, Neuser P, Lueer K, Klemmer A, Schade-Brittinger C, Harnisch S, Garn H, Renz H, Homburg U, Renz J, Kirsten A, Pedersen F, Müller M, Vogelmeier CF, Watz H.

Respir Res. 2018 Apr 4;19(1):55. doi: 10.1186/s12931-018-0751-x.

9.

Neutrophil extracellular trap formation is regulated by CXCR2 in COPD neutrophils.

Pedersen F, Waschki B, Marwitz S, Goldmann T, Kirsten A, Malmgren A, Rabe KF, Uddin M, Watz H.

Eur Respir J. 2018 Apr 12;51(4). pii: 1700970. doi: 10.1183/13993003.00970-2017. Print 2018 Apr. No abstract available.

PMID:
29449427
10.

Effect of 12 weeks of once-daily tiotropium/olodaterol on exercise endurance during constant work-rate cycling and endurance shuttle walking in chronic obstructive pulmonary disease.

Maltais F, O'Donnell D, Gáldiz Iturri JB, Kirsten AM, Singh D, Hamilton A, Tetzlaff K, Zhao Y, Casaburi R.

Ther Adv Respir Dis. 2018 Jan-Dec;12:1753465818755091. doi: 10.1177/1753465818755091.

11.

Physical Activity and Fatigue in Patients with Sarcoidosis.

Bahmer T, Watz H, Develaska M, Waschki B, Rabe KF, Magnussen H, Kirsten D, Kirsten AM.

Respiration. 2018;95(1):18-26. doi: 10.1159/000481827. Epub 2017 Nov 9.

12.

Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extension.

Richeldi L, Kreuter M, Selman M, Crestani B, Kirsten AM, Wuyts WA, Xu Z, Bernois K, Stowasser S, Quaresma M, Costabel U.

Thorax. 2018 Jun;73(6):581-583. doi: 10.1136/thoraxjnl-2016-209701. Epub 2017 Oct 9.

13.

Prevalence of asthma-like symptoms with ageing.

Jarvis D, Newson R, Janson C, Corsico A, Heinrich J, Anto JM, Abramson MJ, Kirsten AM, Zock JP, Bono R, Demoly P, Leynaert B, Raherison C, Pin I, Gislason T, Jogi R, Schlunssen V, Svanes C, Watkins J, Weyler J, Pereira-Vega A, Urrutia I, Gullón JA, Forsberg B, Probst-Hensch N, Boezen HM, Martinez-Moratalla Rovira J, Accordini S, de Marco R, Burney P.

Thorax. 2018 Jan;73(1):37-48. doi: 10.1136/thoraxjnl-2016-209596. Epub 2017 Oct 3.

14.
15.

Brain Activation during Perception and Anticipation of Dyspnea in Chronic Obstructive Pulmonary Disease.

Esser RW, Stoeckel MC, Kirsten A, Watz H, Taube K, Lehmann K, Magnussen H, Büchel C, von Leupoldt A.

Front Physiol. 2017 Aug 23;8:617. doi: 10.3389/fphys.2017.00617. eCollection 2017.

16.

Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.

Cahn A, Hamblin JN, Begg M, Wilson R, Dunsire L, Sriskantharajah S, Montembault M, Leemereise CN, Galinanes-Garcia L, Watz H, Kirsten AM, Fuhr R, Hessel EM.

Pulm Pharmacol Ther. 2017 Oct;46:69-77. doi: 10.1016/j.pupt.2017.08.008. Epub 2017 Aug 17.

17.

Physical activity patterns and clusters in 1001 patients with COPD.

Mesquita R, Spina G, Pitta F, Donaire-Gonzalez D, Deering BM, Patel MS, Mitchell KE, Alison J, van Gestel AJ, Zogg S, Gagnon P, Abascal-Bolado B, Vagaggini B, Garcia-Aymerich J, Jenkins SC, Romme EA, Kon SS, Albert PS, Waschki B, Shrikrishna D, Singh SJ, Hopkinson NS, Miedinger D, Benzo RP, Maltais F, Paggiaro P, McKeough ZJ, Polkey MI, Hill K, Man WD, Clarenbach CF, Hernandes NA, Savi D, Wootton S, Furlanetto KC, Cindy Ng LW, Vaes AW, Jenkins C, Eastwood PR, Jarreta D, Kirsten A, Brooks D, Hillman DR, Sant'Anna T, Meijer K, Dürr S, Rutten EP, Kohler M, Probst VS, Tal-Singer R, Gil EG, den Brinker AC, Leuppi JD, Calverley PM, Smeenk FW, Costello RW, Gramm M, Goldstein R, Groenen MT, Magnussen H, Wouters EF, ZuWallack RL, Amft O, Watz H, Spruit MA.

Chron Respir Dis. 2017 Aug;14(3):256-269. doi: 10.1177/1479972316687207. Epub 2017 Feb 24.

18.

Prognosis and longitudinal changes of physical activity in idiopathic pulmonary fibrosis.

Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H.

BMC Pulm Med. 2017 Jul 25;17(1):104. doi: 10.1186/s12890-017-0444-0.

19.

Improvement in 24-hour bronchodilation and symptom control with aclidinium bromide versus tiotropium and placebo in symptomatic patients with COPD: post hoc analysis of a Phase IIIb study.

Beier J, Mroz R, Kirsten AM, Chuecos F, Gil EG.

Int J Chron Obstruct Pulmon Dis. 2017 Jun 14;12:1731-1740. doi: 10.2147/COPD.S121723. eCollection 2017.

20.

Aclidinium bromide improves symptoms and sleep quality in COPD: a pilot study.

Magnussen H, Arzt M, Andreas S, Plate T, Ribera A, Seoane B, Watz H, Kirsten AM.

Eur Respir J. 2017 Jun 22;49(6). pii: 1700485. doi: 10.1183/13993003.00485-2017. Print 2017 Jun. No abstract available.

21.

Effects of the CXCR2 antagonist AZD5069 on lung neutrophil recruitment in asthma.

Watz H, Uddin M, Pedersen F, Kirsten A, Goldmann T, Stellmacher F, Groth E, Larsson B, Böttcher G, Malmgren A, Kraan M, Rabe KF.

Pulm Pharmacol Ther. 2017 Aug;45:121-123. doi: 10.1016/j.pupt.2017.05.012. Epub 2017 May 23. No abstract available.

PMID:
28549850
22.

Effects of combined tiotropium/olodaterol on inspiratory capacity and exercise endurance in COPD.

O'Donnell DE, Casaburi R, Frith P, Kirsten A, De Sousa D, Hamilton A, Xue W, Maltais F.

Eur Respir J. 2017 Apr 19;49(4). pii: 1601348. doi: 10.1183/13993003.01348-2016. Print 2017 Apr.

23.

Analysis of nocturnal actigraphic sleep measures in patients with COPD and their association with daytime physical activity.

Spina G, Spruit MA, Alison J, Benzo RP, Calverley PMA, Clarenbach CF, Costello RW, Donaire-Gonzalez D, Dürr S, Garcia-Aymerich J, van Gestel AJR, Gramm M, Hernandes NA, Hill K, Hopkinson NS, Jarreta D, Kohler M, Kirsten AM, Leuppi JD, Magnussen H, Maltais F, Man WD, McKeough ZJ, Mesquita R, Miedinger D, Pitta F, Singh SJ, Smeenk FWJM, Tal-Singer R, Vagaggini B, Waschki B, Watz H, Wouters EFM, Zogg S, den Brinker AC.

Thorax. 2017 Aug;72(8):694-701. doi: 10.1136/thoraxjnl-2016-208900. Epub 2017 Jan 12.

24.

Physical activity, airway resistance and small airway dysfunction in severe asthma.

Bahmer T, Waschki B, Schatz F, Herzmann C, Zabel P, Kirsten AM, Rabe KF, Watz H; ERA-Study Group.

Eur Respir J. 2017 Jan 4;49(1). pii: 1601827. doi: 10.1183/13993003.01827-2016. Print 2017 Jan. No abstract available.

25.

Fast onset of action of glycopyrronium compared with tiotropium in patients with moderate to severe COPD - A randomised, multicentre, crossover trial.

Watz H, Mailänder C, May C, Baier M, Kirsten AM.

Pulm Pharmacol Ther. 2017 Feb;42:13-20. doi: 10.1016/j.pupt.2016.12.001. Epub 2016 Dec 9.

PMID:
27940287
26.

Angiopoietin-like protein 4 and cardiovascular function in COPD.

Waschki B, Kirsten AM, Holz O, Meyer T, Lichtinghagen R, Rabe KF, Magnussen H, Welte T, Watz H, Janciauskiene S.

BMJ Open Respir Res. 2016 Oct 31;3(1):e000161. eCollection 2016.

27.

Efficacy and safety of aclidinium/formoterol versus salmeterol/fluticasone: a phase 3 COPD study.

Vogelmeier C, Paggiaro PL, Dorca J, Sliwinski P, Mallet M, Kirsten AM, Beier J, Seoane B, Segarra RM, Leselbaum A.

Eur Respir J. 2016 Oct;48(4):1030-1039. doi: 10.1183/13993003.00216-2016. Epub 2016 Aug 4.

28.

Evaluation of the effects of olodaterol on exercise endurance in patients with chronic obstructive pulmonary disease: results from two 6-week crossover studies.

Maltais F, Kirsten AM, Hamilton A, De Sousa D, Voß F, Decramer M.

Respir Res. 2016 Jul 6;17(1):77. doi: 10.1186/s12931-016-0389-5.

30.

Clinical Correlates of Reduced Physical Activity in Idiopathic Pulmonary Fibrosis.

Bahmer T, Kirsten AM, Waschki B, Rabe KF, Magnussen H, Kirsten D, Gramm M, Hummler S, Brunnemer E, Kreuter M, Watz H.

Respiration. 2016;91(6):497-502. doi: 10.1159/000446607. Epub 2016 Jun 1.

31.

Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial.

Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, Disse B, Finnigan H, Calverley PM.

Lancet Respir Med. 2016 May;4(5):390-8. doi: 10.1016/S2213-2600(16)00100-4. Epub 2016 Apr 7.

PMID:
27066739
32.

Interplay between seven secondary metal uptake systems is required for full metal resistance of Cupriavidus metallidurans.

Herzberg M, Bauer L, Kirsten A, Nies DH.

Metallomics. 2016 Mar;8(3):313-26. doi: 10.1039/c5mt00295h.

PMID:
26979555
33.

Reduced physical activity in lymphangioleiomyomatosis compared with COPD and healthy controls: disease-specific impact and clinical correlates.

Bahmer T, Watz H, Waschki B, Gramm M, Magnussen H, Rabe KF, Wirtz H, Kirsten D, Kirsten A.

Thorax. 2016 Jul;71(7):662-3. doi: 10.1136/thoraxjnl-2015-207852. Epub 2016 Mar 11.

PMID:
26968971
34.

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance.

Beeh KM, Kirsten AM, Dusser D, Sharma A, Cornelissen P, Sigmund R, Moroni-Zentgraf P, Dahl R.

J Aerosol Med Pulm Drug Deliv. 2016 Oct;29(5):406-415. Epub 2016 Feb 9.

35.

Lung function changes over time following withdrawal of inhaled corticosteroids in patients with severe COPD.

Magnussen H, Tetzlaff K, Bateman ED, Watz H, Kirsten AM, Wouters EF, Disse B, Finnigan H, Rodriguez-Roisin R, Calverley PM.

Eur Respir J. 2016 Feb;47(2):651-4. doi: 10.1183/13993003.01644-2015. Epub 2015 Nov 19. No abstract available.

36.

Neutrophil extracellular trap formation and extracellular DNA in sputum of stable COPD patients.

Pedersen F, Marwitz S, Holz O, Kirsten A, Bahmer T, Waschki B, Magnussen H, Rabe KF, Goldmann T, Uddin M, Watz H.

Respir Med. 2015 Oct;109(10):1360-2. doi: 10.1016/j.rmed.2015.08.008. Epub 2015 Aug 22.

37.

Structural Brain Changes in Patients With COPD.

Esser RW, Stoeckel MC, Kirsten A, Watz H, Taube K, Lehmann K, Petersen S, Magnussen H, von Leupoldt A.

Chest. 2016 Feb;149(2):426-434. doi: 10.1378/chest.15-0027. Epub 2016 Jan 12.

PMID:
26203911
38.

Disease Progression and Changes in Physical Activity in Patients with Chronic Obstructive Pulmonary Disease.

Waschki B, Kirsten AM, Holz O, Mueller KC, Schaper M, Sack AL, Meyer T, Rabe KF, Magnussen H, Watz H.

Am J Respir Crit Care Med. 2015 Aug 1;192(3):295-306. doi: 10.1164/rccm.201501-0081OC.

PMID:
26020495
39.

Allergen-induced asthmatic responses modified by a GATA3-specific DNAzyme.

Krug N, Hohlfeld JM, Kirsten AM, Kornmann O, Beeh KM, Kappeler D, Korn S, Ignatenko S, Timmer W, Rogon C, Zeitvogel J, Zhang N, Bille J, Homburg U, Turowska A, Bachert C, Werfel T, Buhl R, Renz J, Garn H, Renz H.

N Engl J Med. 2015 May 21;372(21):1987-95. doi: 10.1056/NEJMoa1411776. Epub 2015 May 17.

40.

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease.

Beeh KM, Westerman J, Kirsten AM, Hébert J, Grönke L, Hamilton A, Tetzlaff K, Derom E.

Pulm Pharmacol Ther. 2015 Jun;32:53-9. doi: 10.1016/j.pupt.2015.04.002. Epub 2015 May 6.

41.

The safety and tolerability of oral AZD5069, a selective CXCR2 antagonist, in patients with moderate-to-severe COPD.

Kirsten AM, Förster K, Radeczky E, Linnhoff A, Balint B, Watz H, Wray H, Salkeld L, Cullberg M, Larsson B.

Pulm Pharmacol Ther. 2015 Apr;31:36-41. doi: 10.1016/j.pupt.2015.02.001. Epub 2015 Feb 11.

PMID:
25681277
42.

Multi-analyte profiling of inflammatory mediators in COPD sputum--the effects of processing.

Pedersen F, Holz O, Lauer G, Quintini G, Kiwull-Schöne H, Kirsten AM, Magnussen H, Rabe KF, Goldmann T, Watz H.

Cytokine. 2015 Feb;71(2):401-4. doi: 10.1016/j.cyto.2014.10.008. Epub 2014 Nov 15.

PMID:
25464927
43.

Bioactive and thermally compatible glass coating on zirconia dental implants.

Kirsten A, Hausmann A, Weber M, Fischer J, Fischer H.

J Dent Res. 2015 Feb;94(2):297-303. doi: 10.1177/0022034514559250. Epub 2014 Nov 24.

44.
45.

Withdrawal of inhaled glucocorticoids and exacerbations of COPD.

Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM; WISDOM Investigators.

N Engl J Med. 2014 Oct 2;371(14):1285-94. doi: 10.1056/NEJMoa1407154. Epub 2014 Sep 8.

46.

Effects of beclomethason/formoterol and budesonide/formoterol fixed combinations on lung function and airway inflammation in patients with mild to moderate asthma--an exploratory study.

Kirsten AM, Watz H, Brindicci C, Piccinno A, Magnussen H.

Pulm Pharmacol Ther. 2015 Apr;31:79-84. doi: 10.1016/j.pupt.2014.08.007. Epub 2014 Sep 4.

PMID:
25194884
47.

Stepwise withdrawal of inhaled corticosteroids in COPD patients receiving dual bronchodilation: WISDOM study design and rationale.

Magnussen H, Watz H, Kirsten A, Decramer M, Dahl R, Calverley PM, Towse L, Finnigan H, Tetzlaff K, Disse B.

Respir Med. 2014 Apr;108(4):593-9. doi: 10.1016/j.rmed.2014.01.002. Epub 2014 Jan 15.

48.

[Bronchodilator therapy of COPD].

Kirsten AM, Watz H, Magnussen H.

Dtsch Med Wochenschr. 2014 Feb;139(6):264-7. doi: 10.1055/s-0033-1360019. Epub 2014 Jan 28. German. No abstract available.

PMID:
24473845
49.

A cusp supporting framework design can decrease critical stresses in veneered molar crowns.

Kirsten A, Parkot D, Raith S, Fischer H.

Dent Mater. 2014 Mar;30(3):321-6. doi: 10.1016/j.dental.2013.12.004. Epub 2013 Dec 31.

PMID:
24388004
50.

Two-photon laser scanning microscopy as a useful tool for imaging and evaluating macrophage-, IL-4 activated macrophage- and osteoclast-based in vitro degradation of beta-tricalcium phosphate bone substitute material.

Duarte Campos DF, Vogt M, Lindner M, Kirsten A, Weber M, Megens RT, Pyta J, Zenke M, Van Zandvoort M, Fischer H.

Microsc Res Tech. 2014 Feb;77(2):143-52. doi: 10.1002/jemt.22321. Epub 2013 Nov 26.

PMID:
24282165

Supplemental Content

Loading ...
Support Center